Yoga for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers: Results of a Randomized Controlled Trial [0.03%]
胸部放疗患者的瑜伽干预：一项随机对照试验及其家庭照料者的 secondary study 结果分析
Kathrin Milbury,Aileen Chen,Yisheng Li et al.
Kathrin Milbury et al.
Purpose: Patients with advanced thoracic cancers undergoing standard radiotherapy (RT) have a high risk of experiencing performance declines and poor quality of life (QOL). Exercise programs may improve objective and subj...
Attitudes, Practices, and Barriers to Spiritual Care for Patients With Cancer: An International Survey [0.03%]
癌症患者灵性照护的态度、实践与障碍：一项国际调查
Carla Ida Ripamonti,Junita Henry,Christina M Puchalski et al.
Carla Ida Ripamonti et al.
Purpose: Spiritual care is recognized by the WHO and consensus frameworks as integral to whole-person oncology care, yet its integration into practice remains limited. Global data on clinician beliefs, practices, and barr...
Donor Selection in the Post-Transplant Cyclophosphamide Era: Do the Little Things Matter? [0.03%]
后环磷酰胺时代供者选择：细节决定成败？
Richard A Newcomb,Yi-Bin Chen
Richard A Newcomb
Provider Follow-Up and Adherence to Imaging Surveillance Recommendations for Lung Cancer Survivors in a Nationwide Health Care System [0.03%]
全国范围内医疗体系中肺癌幸存者影像监测建议的提供者随访及依从性研究
Julie T Wu,Nicole Lin,Scott V Adams et al.
Julie T Wu et al.
Purpose: With the growing number of cancer survivors and projected shortages of oncology providers, understanding who delivers survivorship care has important implications for care quality. We examined follow-up provider ...
Efficacy and Safety of 177Lu-PSMA-617 in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer [0.03%]
177Lu-PSMA-617治疗老年转移性去势抵抗性前列腺癌的疗效和安全性
Daniel Sentana-Lledo,Avina Rami,Caiwei Zhong et al.
Daniel Sentana-Lledo et al.
Purpose: 177Lu-PSMA-617 (LuPSMA) is an approved prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy for men with metastatic castration-resistant prostate cancer (mCRPC). Older patients, particul...
Implementation of a Model Program at an Independent Community Oncology Practice for the Outpatient Administration of B-Cell Maturation Antigen-Directed Bispecific Antibody Step-Up Doses [0.03%]
独立社区肿瘤实践门诊给药模型程序的实施：B细胞成熟抗原导向双特异性抗体加量药物
Yonatan Resnick,Patrick Boland,John P Winters
Yonatan Resnick
Regulatory approval of B-cell maturation antigen (BCMA)-CD3 bispecific antibodies (BsAbs) has revolutionized the treatment of patients with heavily pretreated relapsed or refractory multiple myeloma. Label-recommended premedications and ste...
Insurance Disparity in Novel Hormonal Therapy Initiation in Patients With Metastatic Hormone-Sensitive Prostate Cancer: Medicare Advantage Versus Traditional Medicare [0.03%]
关于转移性激素敏感型前列腺癌患者新型激素治疗起始的保险差异：医疗保险优势计划与传统医疗保险的对比分析
Baqir Jafry,Chuan Angel Lu,Jonathan Ji et al.
Baqir Jafry et al.
Purpose: To examine whether Medicare Advantage (MA) enrollment is associated with differences in the timeliness of novel hormonal therapy (NHT) initiation, including abiraterone, enzalutamide, apalutamide, and darolutamid...
Toward Sustainable Hematology/Oncology Fellowship Training Through Career-Aligned Specialization [0.03%]
基于职业导向的专业化促进血液学/肿瘤学住院医师培训的可持续发展
Ryan C Augustin,Alexandra P Wolanskyj-Spinner,Lori J Rosenstein et al.
Ryan C Augustin et al.
The traditional combined hematology and oncology fellowship model is increasingly strained by accelerating subspecialization and therapeutic complexity. This commentary focuses on structural reforms within fellowship training to better alig...
Evaluating Effective Biomarker Testing for Advanced Non-Small Cell Lung Cancer in US Community Oncology Practices [0.03%]
评估美国社区肿瘤实践中的晚期非小细胞肺癌的有效生物标志物检测
Christian A Thomas,Sibel Blau,Heather Neuhalfen et al.
Christian A Thomas et al.
Purpose: Biomarker testing, including immunohistochemistry (IHC) and next-generation sequencing, is the standard of care in advanced non-small cell lung cancer (NSCLC) for identifying actionable mutations such as EGFR, AL...
Illusion of Comprehensive Testing in Non-Small Cell Lung Cancer: Why Coverage, Sensitivity, and Reporting Matter [0.03%]
非小细胞肺癌全面检测的误区：检测范围、灵敏度和报告解读的重要性
Teja Voruganti,Xiaoke Wang,Christiana Davis et al.
Teja Voruganti et al.